Table 4 |
|||
| Postdosimetric parameters (hormone-naïve, monotherapy: n = 103) | |||
| Bounce (-) (n=74) | Bounce (+) (n=29) | P value | |
| (mean ± SD) | (mean ± SD) | (t-test) | |
| Age (year) | 68.8 ± 6.1 | 66.1 ± 7.7 | 0.060 |
| PV at postdosimetry (mL) | 27.9 ± 8.0 | 30.8 ± 8.2 | 0.109 |
| %D90 (%) | 110.1 ± 10.4 | 112.1 ± 8.0 | 0.338 |
| D90 (Gy) | 167.6 ± 17.6 | 164.3 ± 12.5 | 0.360 |
| V100 (%) | 93.6 ± 3.8 | 94.4 ± 2.7 | 0.272 |
| V150 (%) | 62.7 ± 8.9 | 65.5 ± 8.8 | 0.163 |
| R100 (mL) | 0.10 ± 0.20 | 0.10 ± 0.10 | 0.936 |
| Urethral volume (mL) | 0.55 ± 0.26 | 0.42 ± 0.23 | 0.019 |
| %UD90 (%) | 95.6 ± 12.1 | 104.7 ± 11.3 | 0.001 |
| UD90 (Gy) | 145.3 ± 18.2 | 153.3 ± 16.2 | 0.041 |
| %UD30 (%) | 140.2 ± 16.1 | 151.5 ± 21.8 | 0.005 |
| Minimal urethral dose (Gy) | 107.5 ± 19.3 | 119.1 ± 16.6 | 0.006 |
| BED (Gy2) | 177.5 ± 19.7 | 173.7 ± 13.9 | 0.354 |
Tanaka et al. BMC Urology 2012 12:28 doi:10.1186/1471-2490-12-28
